Of those 39 patients receiving therapeutic agents with a known higher risk of HZ reactivation (immunomodulators, JAK-2-Inhibitors, proteasome inhibitors, long-term chronic steroid) all were treated for Multiple Myeloma. Here, JAK2 is linked to AL amyloidosis.